Parvoduk

RSS

Lapsed

This medicine's authorisation has lapsed

live attenuated Muscovy duck parvovirus
MedicineVeterinaryLapsed

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Parvoduk has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (279.17 kB - PDF)

Bekijk

español (ES) (388.86 kB - PDF)

Bekijk

čeština (CS) (432.85 kB - PDF)

Bekijk

dansk (DA) (386.36 kB - PDF)

Bekijk

Deutsch (DE) (392.74 kB - PDF)

Bekijk

eesti (ET) (372.5 kB - PDF)

Bekijk

ελληνικά (EL) (456.39 kB - PDF)

Bekijk

français (FR) (390.28 kB - PDF)

Bekijk

hrvatski (HR) (547.54 kB - PDF)

Bekijk

italiano (IT) (391.31 kB - PDF)

Bekijk

latviešu (LV) (456.12 kB - PDF)

Bekijk

lietuvių (LT) (421.48 kB - PDF)

Bekijk

magyar (HU) (449.76 kB - PDF)

Bekijk

Malti (MT) (440.69 kB - PDF)

Bekijk

Nederlands (NL) (388.36 kB - PDF)

Bekijk

polski (PL) (432.82 kB - PDF)

Bekijk

português (PT) (389.06 kB - PDF)

Bekijk

română (RO) (418.94 kB - PDF)

Bekijk

slovenčina (SK) (436.71 kB - PDF)

Bekijk

slovenščina (SL) (428.53 kB - PDF)

Bekijk

suomi (FI) (387.48 kB - PDF)

Bekijk

svenska (SV) (386.11 kB - PDF)

Bekijk

Product information

български (BG) (1.19 MB - PDF)

Bekijk

español (ES) (804.6 kB - PDF)

Bekijk

čeština (CS) (1.03 MB - PDF)

Bekijk

dansk (DA) (817.13 kB - PDF)

Bekijk

Deutsch (DE) (901.86 kB - PDF)

Bekijk

eesti (ET) (803.72 kB - PDF)

Bekijk

ελληνικά (EL) (1.2 MB - PDF)

Bekijk

français (FR) (816.73 kB - PDF)

Bekijk

hrvatski (HR) (1.23 MB - PDF)

Bekijk

italiano (IT) (816.1 kB - PDF)

Bekijk

latviešu (LV) (1.05 MB - PDF)

Bekijk

lietuvių (LT) (953.35 kB - PDF)

Bekijk

magyar (HU) (997.58 kB - PDF)

Bekijk

Malti (MT) (1.06 MB - PDF)

Bekijk

Nederlands (NL) (808.14 kB - PDF)

Bekijk

polski (PL) (1.17 MB - PDF)

Bekijk

português (PT) (803.42 kB - PDF)

Bekijk

română (RO) (936.44 kB - PDF)

Bekijk

slovenčina (SK) (1.06 MB - PDF)

Bekijk

slovenščina (SL) (1.06 MB - PDF)

Bekijk

suomi (FI) (791.59 kB - PDF)

Bekijk

svenska (SV) (796.96 kB - PDF)

Bekijk

Íslenska (IS) (803.26 kB - PDF)

Bekijk

norsk (NO) (815.13 kB - PDF)

Bekijk
Latest procedure affecting product information:R/0006
09/01/2019

български (BG) (189.97 kB - PDF)

Bekijk

español (ES) (281.53 kB - PDF)

Bekijk

čeština (CS) (304.72 kB - PDF)

Bekijk

dansk (DA) (298.36 kB - PDF)

Bekijk

Deutsch (DE) (302.28 kB - PDF)

Bekijk

eesti (ET) (285.5 kB - PDF)

Bekijk

ελληνικά (EL) (325.92 kB - PDF)

Bekijk

français (FR) (335.93 kB - PDF)

Bekijk

hrvatski (HR) (307.68 kB - PDF)

Bekijk

italiano (IT) (299.37 kB - PDF)

Bekijk

latviešu (LV) (340.5 kB - PDF)

Bekijk

lietuvių (LT) (297.31 kB - PDF)

Bekijk

magyar (HU) (303.78 kB - PDF)

Bekijk

Malti (MT) (306.38 kB - PDF)

Bekijk

Nederlands (NL) (313.36 kB - PDF)

Bekijk

polski (PL) (299.63 kB - PDF)

Bekijk

português (PT) (297.7 kB - PDF)

Bekijk

română (RO) (312.51 kB - PDF)

Bekijk

slovenčina (SK) (304.5 kB - PDF)

Bekijk

slovenščina (SL) (297.92 kB - PDF)

Bekijk

suomi (FI) (295.81 kB - PDF)

Bekijk

svenska (SV) (293.03 kB - PDF)

Bekijk

Íslenska (IS) (292.58 kB - PDF)

Bekijk

norsk (NO) (298.06 kB - PDF)

Bekijk

Product details

Name of medicine
Parvoduk
Active substance
live attenuated Muscovy duck parvovirus
International non-proprietary name (INN) or common name
live attenuated Muscovy duck parvovirus
Species
Ducks
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01BD03

Pharmacotherapeutic group

  • duck parvovirus
  • Live viral vaccines
  • Immunologicals for aves

Therapeutic indication

Active immunisation of ducks to prevent mortality1 and to reduce weight loss and lesions of duck parvovirosis and Derzsy's disease.


1In absence of maternally derived antibodies.

Authorisation details

EMA product number
EMEA/V/C/002740
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
11/04/2014
Lapse of marketing authorisation
01/04/2019
Revision
2

Assessment history

This page was last updated on

Share this page